Adaptive and innate immune system via tumor-antigen presentation and co-stimulation

The 'Adaptive and innate immune system via tumor-antigen presentation and co-stimulation' refers to the integrated immune response required to identify and eliminate malignant cells. This process begins with the innate immune system's recognition of tumor-derived 'danger signals' and the subsequent capture of tumor antigens by professional antigen-presenting cells (APCs), such as dendritic cells (Mellman & Steinman, 2001, Nature). These APCs process and present the antigens on Major Histocompatibility Complex (MHC) molecules to T-cell receptors (TCRs). However, TCR engagement alone is insufficient for activation; a second co-stimulatory signal, typically provided by the interaction of CD80/86 on APCs with CD28 on T-cells, is essential for robust T-cell proliferation and effector function (Chen & Flies, 2013, Nature Reviews Immunology). In the context of cancer, this pathway is often suppressed by 'checkpoints' like CTLA-4 and PD-1, which inhibit antigen presentation and T-cell activity (Gajewski et al., 2013, Nature Medicine). Therapeutic interventions, such as checkpoint inhibitors and STING agonists, aim to restore or amplify these innate-adaptive links to promote effective anti-tumor immunity (Corrales et al., 2015, Cell Reports). The coordination between innate sensing and adaptive execution is the cornerstone of effective cancer immunosurveillance. Consequently, this 'target' represents a multi-step biological cascade involving numerous receptors and ligands rather than a single druggable protein.

Other names

Cancer-Immunity CycleAntigen presentation and co-stimulationInnate-adaptive immune bridgingTumor immune surveillance

Drugs targeting this pathway work by either blocking inhibitory 'checkpoint' signals (e.g., CTLA-4, PD-1) that prevent antigen presentation and T-cell activation, or by providing agonistic signals to co-stimulatory receptors (e.g., 4-1BB, OX40) and innate sensors (e.g., STING, TLRs) to enhance the immune response against tumor antigens.